Correction: ODI Pharma AB: Publication of half-year report 2021
Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021. In the previous report, the cost of goods sold was incorrect for the period and first six months, thereby impacting the operating profit and below in profit and loss. Further, the finished goods and goods for resale in the balance sheet has been adjusted. Also, other equity including result for the period is adjusted in the balance sheet. Finally, change in inventories and ongoing works is adjusted in the cash flow statement, thereby impacting the cash flow for the period. The revised half-
